Unituxin Appeal Win Suggests NICE STA Process Is Not Appropriate For Pediatric Orphan Drugs
Executive Summary
The UK charity Solving Kids’ Cancer has won an appeal against a NICE decision declining to recommend United Therapeutics Unituxin (dinutuximab) for treating high-risk neuroblastoma in pediatric populations. The case raises questions over whether NICE's standard technology appraisals are appropriate for medicines for rare conditions in children.
You may also be interested in...
Lessons From Europe: Orphan Drug Valuations Show Limits Of Cost Effectiveness
Biogen, Sanofi executives says US should learn from experience of European health technology assessment bodies as Institute for Clinical and Economic Review embarks on initiative to adapt its value framework to orphan drugs.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.